Ophthalmology and Therapy (May 2023)

Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry

  • Antonio Vitale,
  • Francesca Della Casa,
  • Silvana Guerriero,
  • Gaafar Ragab,
  • Angela Mauro,
  • Valeria Caggiano,
  • Marco Cattalini,
  • Emanuela Del Giudice,
  • Rossella Favale,
  • Carla Gaggiano,
  • Irene Bellicini,
  • Maria Pia Paroli,
  • Mohamed Tharwat Hegazy,
  • Jurgen Sota,
  • Abdurrahman Tufan,
  • Alberto Balistreri,
  • Ibrahim Almaghlouth,
  • Francesco La Torre,
  • Ewa Więsik-Szewczyk,
  • Maria Tarsia,
  • Andrea Hinojosa-Azaola,
  • Eduardo Martín-Nares,
  • Bruno Frediani,
  • Gian Marco Tosi,
  • Alex Fonollosa,
  • José Hernández-Rodríguez,
  • Rana Hussein Amin,
  • Giuseppe Lopalco,
  • Donato Rigante,
  • Luca Cantarini,
  • Claudia Fabiani

DOI
https://doi.org/10.1007/s40123-023-00712-1
Journal volume & issue
Vol. 12, no. 4
pp. 1957 – 1971

Abstract

Read online

Abstract Introduction Scientific evidence of the effectiveness of the tumor necrosis factor inhibitor adalimumab (ADA) in pediatric patients with non-infectious non-anterior uveitis is still limited. The aim of this study is to investigate the therapeutic role of ADA in a cohort of pediatric patients with non-anterior uveitis. Methods This is an international multicenter study analyzing real-life data referred to pediatric patients treated with ADA for intermediate uveitis/pars planitis, posterior uveitis and panuveitis. Data were drawn from the AutoInflammatory Disease Alliance (AIDA) registry for patients with uveitis. Results Twenty-one patients (36 affected eyes) were enrolled, and all patients benefited from ADA administration. In detail, 11 patients (19 affected eyes) did not experience further ocular inflammation after ADA introduction; 10 cases (17 affected eyes) showed a significant clinical improvement consisting of a decrease in severity and/or frequency of ocular relapses. The number of ocular flares dropped from 3.91 to 1.1 events/patient/year after ADA introduction (p = 0.0009); macular edema and retinal vasculitis were respectively observed in 18 eyes and 20 eyes at the start of ADA and in 4 eyes and 2 eyes at the last assessment. The mean daily glucocorticoid dosage significantly decreased from 26.8 ± 16.8 mg/day at the start of ADA to 6.25 ± 6.35 mg/day at the last assessment (p = 0.002). Intermediate uveitis/pars planitis (p = 0.01) and posterior uveitis (p = 0.03) were more frequently observed in patients with full response to ADA; panuveitis (p = 0.001) was significantly more frequent among patients continuing to experience uveitic flares. This could be related to a higher use of systemic glucocorticoids (p = 0.002) and conventional immunosuppressants (p = 0.007) at the start of ADA when treating intermediate uveitis/pars planitis. Regarding the safety profile, only one adverse event was reported during ADA treatment, consisting of the development of generalized adenopathy. Conclusions ADA proved to have an effective therapeutic role in all pediatric patients with non-anterior uveitis enrolled in the study. An overall glucocorticoid-sparing effect was observed despite the severity of cases enrolled. A more aggressive treatment of panuveitis and posterior uveitis at start of ADA could increase the likelihood of full response to therapy.

Keywords